Nyxoah to Present at the 44th Annual J.P. Morgan Healthcare ConferenceNyxoah to Present at the 44th Annual J.P. Morgan Healthcare Conference
Nyxoah Announces Issuance of First Tranche of Convertible BondsNyxoah Announces Issuance of First Tranche of Convertible Bonds
Nyxoah Announces Commercial Launch of Genio® Breakthrough Therapy in the NetherlandsNyxoah Announces Commercial Launch of Genio® Breakthrough Therapy in the NetherlandsFirst Genio implants successfully performed at OLVG West and Zuyderland hospitals
Nyxoah to Participate in the Piper Sandler 37th Annual Healthcare ConferenceNyxoah to Participate in the Piper Sandler 37th Annual Healthcare Conference
Nyxoah’s Genio® Therapy Receives Significant 2026 Medicare Reimbursement Increases Under Final CMS RuleNyxoah’s Genio® Therapy Receives Significant 2026 Medicare Reimbursement Increases Under Final CMS Rule
Nyxoah to Participate in the Stifel 2025 Healthcare ConferenceNyxoah to Participate in the Stifel 2025 Healthcare Conference
Nyxoah to Release Third Quarter 2025 Financial Results on November 13, 2025Nyxoah to Release Third Quarter 2025 Financial Results on November 13, 2025
Nyxoah Announces First U.S. Commercial Patients Implanted with Genio® SystemNyxoah Announces First U.S. Commercial Patients Implanted with Genio® System
Nyxoah Provides an Update on Expanded Middle East PresenceNyxoah Provides an Update on Expanded Middle East Presence
Nyxoah Files Patent Infringement Lawsuit Against Inspire Medical Systems, Inc.Nyxoah Files Patent Infringement Lawsuit Against Inspire Medical Systems, Inc.
Nyxoah Announces Upcoming Investor EventsNyxoah Announces Upcoming Investor Events
Nyxoah Announces Preliminary Results for the Second Quarter of 2025Nyxoah Announces Preliminary Results for the Second Quarter of 2025
Nyxoah to Release Second Quarter 2025 Financial Results on August 18, 2025Nyxoah to Release Second Quarter 2025 Financial Results on August 18, 2025
